

606233-2026 - Consultation

Finland – Pharmaceutical products – Request For Information – Supply of Boronophenylalanine for pharmaceutical preparation of compound for BNCT treatment

OJ S 170/2026 03/09/2026

Pre-market consultation notice

Supplies

1. Buyer

1.1. Buyer

Official name: HUS Group, the joint authority for Helsinki and Uusimaa

Email: laakehankinnat@hus.fi

Legal type of the buyer: Body governed by public law

Activity of the contracting authority: Health

2. Procedure

2.1. Procedure

Title: Request For Information – Supply of Boronophenylalanine for pharmaceutical preparation of compound for BNCT treatment

Description: HUS Pharmacy is searching for a new supplier of L-4-boronophenylalanine (synonyms: BPA, borofalan, 4-(borono- 10B)-L-phenylalanine), CAS No [80994-59-8]. The supplied BPA will be used in pharmaceutical preparation of BPA-fructose complex used in BNCT-treatment at HUS Comprehensive Cancer Centre. The aim of this RFI is to survey and identify suppliers with the capability to manufacture BPA on a scale and according to the medicinal grade specifications set by HUS Pharmacy. After this RFI HUS Pharmacy will conduct a formal tendering process to establish a multi-year supplier contract. The estimated consumption of BPA is 2-4 kilograms per year starting from 2028. This number can change, as the accelerator based BNCT treatment is a novel process and thus under constant clinical study and development. The specifications for BPA are set out in Attachment 1 to this notice. We ask the interested parties to provide as much as possible of the following information:

- Approximate minimum and maximum size of order in grams or kilograms, when delivery is from a single production batch.
- Approximate time from order to delivery to Finland. We acknowledge that the production of BPA requires several months to complete.
- Shelf-life of product from batch release. If provider has an ongoing stability program to extend the shelf-life, then the expected future shelf-life information can also be noted.
- Description of the quality assurance of the final product and quality management of the production process.
- Any possible regulatory requirements regarding HUS Pharmacy when delivering boron-10 isotope to Finland, if the providers national regulations have such requirements.
- Information about other possible boron-10 carriers available for BNCT treatment can be provided.

The information can be provided in a format of your choice in English or Finnish. Responses provided by suppliers will be treated confidentially. Interested party can send questions regarding the RFI to HUS Pharmacy with the initial information, and an active discussion can be arranged upon request. RFI can be supplemented based on the dialogue. This is not a contract notice or a request for tenders, but a request for information (RFI). The purpose of the RFI is to assess the market, identify suppliers currently operating in the market, and obtain information on their product portfolios. The RFI does not invite or request the submission of tenders, and this notice does not initiate a competitive tendering process. The information

presented in this notice, as well as any information provided during the market consultation, is preliminary and indicative. HUS is under no obligation to proceed with the procurement or to adopt any procurement method. HUS will not pay any compensation for responding to the RFI or participating in the market consultation. Responding to the RFI does not oblige the supplier to participate in any subsequent competitive tendering process, nor is it a prerequisite for participating in any subsequent procurement procedure. Whether or not a supplier responds to the RFI will have no bearing on the supplier's position in any subsequent competitive tendering process.

2.1.1. Purpose

Main nature of the contract: Supplies

Main classification (cpv): 33600000 Pharmaceutical products

2.1.2. Place of performance

Country subdivision (NUTS): Helsinki-Uusimaa (FI1B1)

Country: Finland

2.1.4. General information

Additional information: Responses to the information request shall be submitted through Hilma or by email to laakehankinnat@hus.fi no later than the deadline specified in this notice.

Legal basis:

Other

Laki julkisista hankinnoista ja käyttöoikeussopimuksista (Hankintalaki) (1397/2016) / Act on Public Procurement and Concession Contracts (1397/2016)

5. Lot

5.1. Lot: LOT-0000

Title: Request For Information – Supply of Boronophenylalanine for pharmaceutical preparation of compound for BNCT treatment

Description: HUS Pharmacy is searching for a new supplier of L-4-boronophenylalanine (synonyms: BPA, borofalan, 4-(borono- 10B)-L-phenylalanine), CAS No [80994-59-8]. The supplied BPA will be used in pharmaceutical preparation of BPA-fructose complex used in BNCT-treatment at HUS Comprehensive Cancer Centre. The aim of this RFI is to survey and identify suppliers with the capability to manufacture BPA on a scale and according to the medicinal grade specifications set by HUS Pharmacy. After this RFI HUS Pharmacy will conduct a formal tendering process to establish a multi-year supplier contract. The estimated consumption of BPA is 2-4 kilograms per year starting from 2028. This number can change, as the accelerator based BNCT treatment is a novel process and thus under constant clinical study and development. The specifications for BPA are set out in Attachment 1 to this notice. We ask the interested parties to provide as much as possible of the following information:

- Approximate minimum and maximum size of order in grams or kilograms, when delivery is from a single production batch.
- Approximate time from order to delivery to Finland. We acknowledge that the production of BPA requires several months to complete.
- Shelf-life of product from batch release. If provider has an ongoing stability program to extend the shelf-life, then the expected future shelf-life information can also be noted.
- Description of the quality assurance of the final product and quality management of the production process.
- Any possible regulatory requirements regarding HUS Pharmacy when delivering boron-10 isotope to Finland, if the providers national regulations have such requirements.
- Information about other possible boron-10 carriers available for BNCT treatment can be provided. The information can be provided in a format of your choice in English or Finnish. Responses

provided by suppliers will be treated confidentially. Interested party can send questions regarding the RFI to HUS Pharmacy with the initial information, and an active discussion can be arranged upon request. RFI can be supplemented based on the dialogue. This is not a contract notice or a request for tenders, but a request for information (RFI). The purpose of the RFI is to assess the market, identify suppliers currently operating in the market, and obtain information on their product portfolios. The RFI does not invite or request the submission of tenders, and this notice does not initiate a competitive tendering process. The information presented in this notice, as well as any information provided during the market consultation, is preliminary and indicative. HUS is under no obligation to proceed with the procurement or to adopt any procurement method. HUS will not pay any compensation for responding to the RFI or participating in the market consultation. Responding to the RFI does not oblige the supplier to participate in any subsequent competitive tendering process, nor is it a prerequisite for participating in any subsequent procurement procedure. Whether or not a supplier responds to the RFI will have no bearing on the supplier's position in any subsequent competitive tendering process.

Internal identifier: 2026-055448-LOT-0001

5.1.1. Purpose

Main nature of the contract: Supplies

Main classification (cpv): 33600000 Pharmaceutical products

5.1.2. Place of performance

Country subdivision (NUTS): Helsinki-Uusimaa (FI1B1)

Country: Finland

5.1.6. General information

Additional information: Responses to the information request shall be submitted through Hilma or by email to laakehankinnat@hus.fi no later than the deadline specified in this notice.

5.1.12. Terms of procurement

Terms of submission:

Electronic submission: Required

Address for submission: <https://www.hankintailmoitukset.fi/en/tendering/procedure/36243/call-for-tenders>

Languages in which tenders or requests to participate may be submitted: Finnish, English

Deadline for receipt of answers: 01/10/2026 10:00:00 (UTC+03:00) Eastern European

Summer Time, Istanbul, Mayotte

8. Organisations

8.1. ORG-0001

Official name: HUS Group, the joint authority for Helsinki and Uusimaa

Registration number: 1567535-0

Department: HUS Apteekki

Postal address: Stenbäckinkatu 9, PL 440

Town: Helsinki

Postcode: 00290

Country subdivision (NUTS): Helsinki-Uusimaa (FI1B1)

Country: Finland

Contact point: HUS Pharmacy

Email: laakehankinnat@hus.fi

Telephone: +35894711

Internet address: <https://www.hus.fi/ammattilaiselle/hus-apteekki>

Roles of this organisation:

Buyer

8.1. ORG-0002

Official name: Hansel Oy (Hilma)

Registration number: FI09880841

Postal address: Mannerheiminaukio 1 A

Town: Helsinki

Postcode: 00100

Country subdivision (NUTS): Helsinki-Uusimaa (FI1B1)

Country: Finland

Email: tekninen@hankintailmoitukset.fi

Telephone: +358 295563630

Internet address: <https://www.hankintailmoitukset.fi>

Roles of this organisation:

TED eSender

Notice information

Notice identifier/version: fb981049-6379-40e7-8419-34ad68cc1532 - 01

Form type: Consultation

Notice type: Pre-market consultation notice

Notice subtype: E1

Notice dispatch date: 02/09/2026 12:04:21 (UTC+03:00) Eastern European Summer Time, Istanbul, Mayotte

Languages in which this notice is officially available: English

Notice publication number: 606233-2026

OJ S issue number: 170/2026

Publication date: 03/09/2026